These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30878666)

  • 1. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.
    Lutz MP; Zalcberg JR; Ducreux M; Adenis A; Allum W; Aust D; Carneiro F; Grabsch HI; Laurent-Puig P; Lordick F; Möhler M; Mönig S; Obermannova R; Piessen G; Riddell A; Röcken C; Roviello F; Schneider PM; Seewald S; Smyth E; van Cutsem E; Verheij M; Wagner AD; Otto F
    Eur J Cancer; 2019 May; 112():1-8. PubMed ID: 30878666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
    Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
    Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
    Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
    Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
    Moehler M; Baltin CT; Ebert M; Fischbach W; Gockel I; Grenacher L; Hölscher AH; Lordick F; Malfertheiner P; Messmann H; Meyer HJ; Palmqvist A; Röcken C; Schuhmacher C; Stahl M; Stuschke M; Vieth M; Wittekind C; Wagner D; Mönig SP
    Gastric Cancer; 2015 Jul; 18(3):550-63. PubMed ID: 25192931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
    Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
    Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
    Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
    Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.
    Hosoda K; Yamashita K; Katada N; Watanabe M
    Gen Thorac Cardiovasc Surg; 2015 Oct; 63(10):549-56. PubMed ID: 26232357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.
    Lutz MP; Zalcberg JR; Ducreux M; Aust D; Bruno MJ; Büchler MW; Delpero JR; Gloor B; Glynne-Jones R; Hartwig W; Huguet F; Laurent-Puig P; Lordick F; Maisonneuve P; Mayerle J; Martignoni M; Neoptolemos J; Rhim AD; Schmied BM; Seufferlein T; Werner J; van Laethem JL; Otto F
    Eur J Cancer; 2017 Jul; 79():41-49. PubMed ID: 28460245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status and challenges of clinical trial on adenocarcinoma of esophagogastric junction].
    Zhou Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):112-118. PubMed ID: 30799533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer.
    Lutz MP; Zalcberg JR; Glynne-Jones R; Ruers T; Ducreux M; Arnold D; Aust D; Brown G; Bujko K; Cunningham C; Evrard S; Folprecht G; Gerard JP; Habr-Gama A; Haustermans K; Holm T; Kuhlmann KF; Lordick F; Mentha G; Moehler M; Nagtegaal ID; Pigazzi A; Pucciarelli S; Roth A; Rutten H; Schmoll HJ; Sorbye H; Van Cutsem E; Weitz J; Otto F
    Eur J Cancer; 2016 Aug; 63():11-24. PubMed ID: 27254838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study.
    Du R; Ming J; Geng J; Zhu X; Zhang Y; Li S; Liu Z; Wang H; Wang Z; Tang L; Zhang X; Wu A; Bu Z; Yan Y; Li Z; Li Y; Li Z; Wang W
    Radiat Oncol; 2022 Mar; 17(1):45. PubMed ID: 35241109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized adenocarcinoma of the esophagogastric junction--is there a standard of care?
    Power DG; Reynolds JV
    Cancer Treat Rev; 2010 Aug; 36(5):400-9. PubMed ID: 20117883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer.
    Veuillez V; Rougier P; Seitz JF
    Best Pract Res Clin Gastroenterol; 2007; 21(6):947-63. PubMed ID: 18070697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neoadjuvant and perioperative treatment of gastric cancer, current studies and new biomarkers].
    Stocker G; Thieme R; Lordick F
    Chirurg; 2021 Jun; 92(6):499-505. PubMed ID: 33566116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.